Pulse Biosciences (PLSE) announced that the FDA has granted approval for the company’s Investigational Device Exemption, allowing Pulse Biosciences to proceed with the initiation of its nPulse Cardiac Catheter Ablation System Study for the treatment of paroxysmal atrial fibrillation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE:
- Pulse Biosciences Holds 2025 Annual Stockholder Meeting
- Pulse Biosciences Partners with MD Anderson for Thyroid Cancer Study
- Pulse Biosciences initiates research collaboration for thyroid cancers treatment
- Pulse Biosciences Updates Investors on Product Advancements
- Pulse Biosciences management to meet virtually with Oppenheimer